Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250

Journal of Clinical Oncology

Volumn 15, Issue 4, 1997, Pages 1529-1537

  Steffens, M G ^a   Boerman, O C ^a   Oosterwijk Wakka, J C ^a   Oosterhof, G O N ^a   Witjes, J A ^a   Koenders, E B ^a   Oyen, W J G ^a   Buijs, W C ^a   Debruyne, F M ^a   Corstens, F H ^a   Oosterwijk, E ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIBODY; IODINE 131; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CG250 I 131; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOSIMETRY; DRUG CLEARANCE; DRUG DISTRIBUTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; KIDNEY CARCINOMA; MALE; NEPHRECTOMY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY;

EID: 17544404888     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.4.1529     Document Type: Article

References (26)

1. Garnick MB, Richie JP: Renal neoplasia, in Brenner BM, Rector FC Jr (eds): The Kidney. Philadelphia, PA, Saunders, 1991, pp 1809-1827
2. DeKernion JB: Renal tumors, in Walsh PC, Gittes RF, Perlmutter AD, et al (eds): Campbell's Urology (ed 6). Philadelphia, PA, Saunders, 1993, pp 1294-1342
3. Köhler G, Milstein C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495-497, 1975
4. Oosterwijk E, Bander NH, Divgi CR, et al: Antibody localization in human renal cell carcinoma: A phase I study of monoclonal antibody G250. J Clin Oncol 11:738-750, 1993
5. 131I-G250) in metastatic renal carcinoma. Eur J Nucl Med 8:819, 1995 (abstr 401)
6. Oosterwijk E, Ruiter DJ, Hoedemaker PJ, et al: Monoclonal antibody G250 recognizes a determinant present in renal cell carcinoma and absent from normal kidney. Int J Cancer 38:489-494, 1986
7. Velders MP, Litvinov SV, Warnaar SO, et al: New chimeric anti-pancarcinoma monoclonal antibody with superior cytotoxicity-mediating potency. Cancer Res 54:1753-1760, 1994
8. Boerman OC, Tibben JG, Massuger LF, et al: Tumour targetting of the anti-ovarian carcinoma X anti-CD3/TCR bispecific monoclonal antibody OC/TR and its parental MOv18 antibody in experimental ovarian cancer. Anticancer Res 15:2169-2174, 1995
9. Fraker PJ, Speck JC: Protein and cell membrane iodination with a sparingly soluble chloramide 1,3,4,6-tetrachloro-3,6-diphenylglucoril. Biochem Biophys Res Commun 80:849-857, 1978
10. Uemura H, Okajima E, Debruyne FM, et al: Internal image anti-idiotype antibodies related to renal cell carcinoma-associated antigen G250. Int J Cancer 56: 609-614, 1994
11. Buijs WC, Massuger LF, Claessens RA, et al: Dosimetric evaluation of immunoscintigraphy using indium-111-labeled monoclonal antibody fragments in patients with ovarian cancer. J Nucl Med 33:1113-1120, 1992
12. Stabin MG: Personel computer software for internal dose assessment in nuclear medicine. J Nucl Med 37:538-546, 1996
13. 131I-labeled chimeric mouse/human IgG1, κ 17-1A monoclonal antibody. J Nucl Med 32:1162-1168, 1991
14. Buist MR, Kenemans P, van Kamp GJ, et al: Minor human antibody response to a mouse and chimeric monoclonal antibody after a single i.v. infusion in ovarian carcinoma patients: A comparison of five assays. Cancer Immunol Immunother 1:24-30, 1995
15. Meredith RF, Khazaeli MB, Grizzle WE, et al: Direct localization comparison of murine and chimeric B72.3 antibodies in patients with colon cancer. Hum Antibodies Hybridomas 4:190-197, 1993
16. Buist MR, Kenemans P, den Hollander W, et al: Kinetics and tissue distribution of the radiolabeled monoclonal antibody MOv18 IgG and F(ab′), fragments in ovarian carcinoma patients. Cancer Res 53:5413-5418, 1993
17. Buchegger F, Mach JP, Pelegrin A, et al: Radiolabeled chimeric anti-CEA monoclonal antibody compared with the original mouse monoclonal antibody for surgically treated colorectal carcinoma. J Nucl Med 36:420-429, 1995
18. Juweid M, Sharkey RM, Markowitz A, et al: Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric or humanized LL2, an anti CD-22 monoclonal antibody. Cancer Res 55:5899-5907, 1995
19. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 346:336-340, 1995
20. 131I-labeled anticolorectal carcinoma human monoclonal antibody LiC) 16.88. Cancer Immunol Immunother 39:397-400, 1994
21. Bander NH, Divgi CR, Finn R, et al: Renal cancer imaging with monoclonal antibody (mAb) G250. J Urol 5:583, 1995 (abstr 1088)
22. Fowler JF: Radiobiological aspects of low dose rates in radioimmunotherapy. Int J Radiat Oncol Biol 18:1261-1269, 1990
23. Vaughan AT, Bradwell AR, Dykes PW, et al: Illusions of tumour killing using radiolabelled antibodies. Lancet 1:1492-1493, 1986
24. Vaughan AT, Anderson P, Dykes PW, et al: Limitations to the killing of tumours using radiolabelled antibodies. Br J Radiol 60:567-578, 1987
25. Larson SM, Carrasquillo JA, Colcher DC, et al: Estimates of radiation absorbed dose for intra peritoneally administered iodine-131 radiolabeled B72.3 monoclonal antibody in patients with peritoneal carcinomatoses. J Nucl Med 32:1661-1667, 1991
26. 131I-labeled chimeric L6 antibody with peripheral blood progenitor cell transfusions. Cancer Res 55:5916-5920, 1995